Johnson & Johnson is constructing its immunology pipeline, closing a $1.25 billion deal for a bispecific antibody in improvement for atopic dermatitis – the second acquisition deal for the indication up to now two weeks. The deal introduced Tuesday will give J&J a Numab Therapeutics drug codenamed NM26. The pharmaceutical large acquires world rights to the experimental therapy, which is […]
